GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » 3-Year FCF Growth Rate

Sino Biopharmaceutical (FRA:SMZ1) 3-Year FCF Growth Rate

: 8.10% (As of Jun. 2023)
View and export this data going back to . Start your Free Trial

Sino Biopharmaceutical's Free Cash Flow per Share for the six months ended in Jun. 2023 was €0.01.

During the past 12 months, Sino Biopharmaceutical's average Free Cash Flow per Share Growth Rate was -40.60% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 8.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 8.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 16.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Sino Biopharmaceutical was 94.60% per year. The lowest was -33.10% per year. And the median was 6.15% per year.


Competitive Comparison

For the Biotechnology subindustry, Sino Biopharmaceutical's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical 3-Year FCF Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's 3-Year FCF Growth Rate falls into.



Sino Biopharmaceutical 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Sino Biopharmaceutical  (FRA:SMZ1) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Sino Biopharmaceutical 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (FRA:SMZ1) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (FRA:SMZ1) Headlines

No Headlines